Gemini Bioproducts, a supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm, has formed a distribution agreement with Celartia. Effective immediately, customers can now purchase Celartia’s line of closed, single-use cell culture cassettes directly from Gemini.

Columbus, OH-based Celartia manufactures the Petaka G3, a closed, single-use, disposable cell culture device that automatically regulates dissolved gasses and pH to provide reliable physioxic culture conditions. The Petaka G3 replaces a variety of traditional and advanced cell culture ware and eliminates the need for most environmental control chambers. The Petaka G3 also established a new product category by providing weeks-long, non-frozen, live cell transportation and storage.

“I am extremely excited to add Celartia’s line of single-use solutions to the Gemini portfolio,” said Brendan Lucey, vice president of business development, Gemini Bio. “In addition to supplying all components of cell growth, we now have a host to grow them on. This addition continues our focus on supporting breakthroughs in the cell therapy field with innovative bioprocessing solutions that allow for an easy transition from R&D to manufacturing.”

Aaron Haubner, vice president and general manager, Celartia, said, “Celartia’s vision is to fundamentally change what people believe is possible in cell culture. Our partnership with Gemini Bio allows us to share that vision with the most advanced cell culture laboratories in the world. This partnership combines Celartia’s innovation and manufacturing expertise with Gemini’s first-rate sales network and potent marketing abilities to better serve the U.S. market.”